Intra-Cellular Therapies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Written by Customer Service on . Posted in Public Companies.

NEW YORK, April 16, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the grant to 266 new employees of inducement stock options to purchase an aggregate of 33,040 shares of its common stock and restricted stock units for an aggregate of 267,729 shares of its common stock under its 2019 Inducement Award Plan. The stock options are exercisable at a price of $15.81 per share, the closing price of Intra-Cellular Therapies’ common stock on March 30, 2020, the grant date. The stock options and restricted stock units were granted as inducements material to each employee’s acceptance of employment with Intra-Cellular Therapies in accordance with Nasdaq Listing Rule 5635(c)(4).Each stock option has a 10-year term. Each stock option and restricted stock unit vests in a series of three equal annual installments on each anniversary of the grant date over a three-year period, subject to the employee’s continued service with Intra-Cellular Therapies through the applicable vesting dates. The stock options and restricted stock units are subject to the terms and conditions of Intra-Cellular Therapies’ 2019 Inducement Award Plan, and the terms and conditions of equity award agreements covering the grants.About Intra-Cellular TherapiesIntra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.ContactIntra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333Burns McClellan, Inc.
Lisa Burns
jgrimaldi@burnsmc.com
212-213-0006MEDIA INQUIRIES:Ana Fullmer
Corporate Media Relations W2Owcg
afullmer@wcgworld.com
202-507-0130

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.